Exposure to selective serotonin reuptake inhibitors in early pregnancy and the risk of miscarriage

Obstetrics and Gynecology

Volumn 124, Issue 4, 2014, Pages 655-661

  Andersen, Jon Trærup ^a   Andersen, Nadia Lyhne ^b   Horwitz, Henrik ^b   Poulsen, Henrik Enghusen ^b   Jimenez Solem, Espen ^b  

^a Mental Health Center Glostrup   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

CITALOPRAM; ESCITALOPRAM; FLUOXETINE; PAROXETINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE;

ADULT; AGE; ARTICLE; COHORT ANALYSIS; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG MEGADOSE; DRUG USE; DRUG WITHDRAWAL; EDUCATIONAL STATUS; FEMALE; FIRST TRIMESTER PREGNANCY; HAZARD RATIO; HUMAN; INCOME; INDUCED ABORTION; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MEDICAL HISTORY; PRENATAL DRUG EXPOSURE; PRESCRIPTION; PRIORITY JOURNAL; RISK FACTOR; SPONTANEOUS ABORTION; TREATMENT WITHDRAWAL; YOUNG ADULT; ABORTION, SPONTANEOUS; CHEMICALLY INDUCED; COMPARATIVE STUDY; CONFIDENCE INTERVAL; DENMARK; DEPRESSIVE DISORDER; INCIDENCE; NEWBORN; PREGNANCY; PREGNANCY COMPLICATIONS; PREGNANCY OUTCOME; PROPORTIONAL HAZARDS MODEL; REFERENCE VALUE; REGISTER; RETROSPECTIVE STUDY; RISK ASSESSMENT;

ABORTION, SPONTANEOUS; ADULT; COHORT STUDIES; CONFIDENCE INTERVALS; DENMARK; DEPRESSIVE DISORDER; FEMALE; HUMANS; INCIDENCE; INFANT, NEWBORN; PREGNANCY; PREGNANCY COMPLICATIONS; PREGNANCY OUTCOME; PREGNANCY TRIMESTER, FIRST; PROPORTIONAL HAZARDS MODELS; REFERENCE VALUES; REGISTRIES; RETROSPECTIVE STUDIES; RISK ASSESSMENT; SEROTONIN UPTAKE INHIBITORS; YOUNG ADULT;

EID: 84922364507     PISSN: 00297844     EISSN: 1873233X     Source Type: Journal    
DOI: 10.1097/AOG.0000000000000447     Document Type: Article

References (32)

1. Chatillon O, Even C. Antepartum depression: prevalence, diagnosis and treatment [in French]. Encephale 2010;36:443-51.
2. Bennett HA, Einarson A, Taddio A, Koren G, Einarson TR. Prevalence of depression during pregnancy: systematic review. Obstet Gynecol 2004;103:698-709.
3. Bonari L, Pinto N, Ahn E, Einarson A, Steiner M, Koren G. Perinatal risks of untreated depression during pregnancy. Can J Psychiatry 2004;49:726-35.
4. Talati A, Wickramaratne PJ, Pilowsky DJ, Alpert JE, Cerda G, Garber J, et al. Remission of maternal depression and child symptoms among single mothers: a STAR∗D-Child report. Soc Psychiatry Psychiatr Epidemiol 2007;42:962-71.
5. Ross LE, Grigoriadis S, Mamisashvili L, Vonderporten EH, Roerecke M, Rehm J, et al. Selected pregnancy and delivery outcomes after exposure to antidepressant medication: a systematic review and meta-analysis. JAMA Psychiatry 2013;70:436-43.
6. Bassiouni BA, Rafei AA. 5-Hydroxytryptamine (serotonin), copper and ceruloplasmin plasma concentrations in spontaneous abortion. Eur J Obstet Gynecol Reprod Biol 1979;9:81-8.
7. Jimenez-Solem E, Andersen JT, Petersen M, Broedbaek K, Andersen NL, Torp-Pedersen C, et al. Prevalence of antidepressant use during pregnancy in Denmark, a nation-wide cohort study. PLoS One 2013;8:e63034.
8. Pastuszak A, Schick-Boschetto B, Zuber C, Feldkamp M, Pinelli M, Sihn S, et al. Pregnancy outcome following firsttrimester exposure to fluoxetine (Prozac). JAMA 1993;269:2246-8.
9. Chambers CD, Johnson KA, Dick LM, Felix RJ, Jones KL. Birth outcomes in pregnant women taking fluoxetine. N Engl J Med 1996;335:1010-5.
10. McElhatton PR, Garbis HM, Eléfant E, Vial T, Bellemin B, Mastroiacovo P, et al. The outcome of pregnancy in 689 women exposed to therapeutic doses of antidepressants. A collaborative study of the European Network of Teratology Information Services (ENTIS). Reprod Toxicol 1996;10:285-94.
11. Goldstein DJ, Corbin LA, Sundell KL. Effects of first-trimester fluoxetine exposure on the newborn. Obstet Gynecol 1997;89:713-8.
12. Kulin NA, Pastuszak A, Sage SR, Schick-Boschetto B, Spivey G, FeldkampM, et al. Pregnancy outcome following maternal use of the new selective serotonin reuptake inhibitors: a prospective controlled multicenter study. JAMA 1998;279:609-10.
13. Sivojelezova A, Shuhaiber S, Sarkissian L, Einarson A, Koren G. Citalopram use in pregnancy: prospective comparative evaluation of pregnancy and fetal outcome. Am J Obstet Gynecol 2005;193:2004-9.
14. Diav-Citrin O, Shechtman S, Weinbaum D, Wajnberg R, Avgil M, Di Gianantonio E, et al. Paroxetine and fluoxetine in pregnancy: a prospective, multicentre, controlled, observational study. Br J Clin Pharmacol 2008;66:695-705.
15. Kjaersgaard MI, Parner ET, Vestergaard M, Sørensen MJ, Olsen J, Christensen J, et al. Prenatal antidepressant exposure and risk of spontaneous abortion- A population-based study. PLoS One 2013;8:e72095.
16. Jimenez-Solem E, Jensen JK, Afzal S, Gislason GH, Torp-Pedersen C, Poulsen HE, et al. Exposure to selective serotonin reuptake inhibitors and the risk of congenital malformations: a nationwide cohort study. BMJ Open 2012;2:e001148.
17. Andersen TF, MadsenM, Jørgensen J, Mellemkjoer L, Olsen JH. The Danish National Hospital Register. A valuable source of data for modern health sciences. Dan Med Bull 1999;46:263-8.
18. Knudsen LB, Olsen J. The danish medical birth registry. Dan Med Bull 1998;45:320-3.
19. The Danish National Board of Health. Project on data quality in the national hospital register. Copenhagen (Denmark): The Danish National Board of Health; 2004.
20. Lohse SR, Farkas DK, Lohse N, Skouby SO, Nielsen FE, Lash TL, et al. Validation of spontaneous abortion diagnoses in the Danish National Registry of Patients. Clin Epidemiol 2010;2:247-50.
21. Kristensen J, Langhoff-Roos J, Skovgaard LT, Kristensen FB. Validation of the danish birth registration. J Clin Epidemiol 1996;49:893-7.
22. Gaist D, Sørensen HT, Hallas J. The Danish prescription registries. Dan Med Bull 1997;44:445-8.
23. Kildemoes HW, Sørensen HT, Hallas J. The danish national prescription registry. Scand J Public Health 2011;39(suppl):38-41.
24. Sørensen HT, Hansen I, Ejlersen E, Sabroe S, Hamburger H. Identification of patients treated with strong analgesics: an assessment of two Danish information systems with respect to epidemiological research. J Med Syst 1996;20:57-65.
25. Von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. BMJ 2007;335:806-8.
26. Andersen AM, Andersen PK, Olsen J, Grønbæk M, Strandberg-Larsen K. Moderate alcohol intake during pregnancy and risk of fetal death. Int J Epidemiol 2012;41:405-13.
27. Baba S, Noda H, Nakayama M, Waguri M, Mitsuda N, Iso H. Risk factors of early spontaneous abortions among Japanese: a matched case-control study. Hum Reprod 2011;26:466-72.
28. George L, Mills JL, Johansson AL, Nordmark A, Olander B, Granath F, et al. Plasma folate levels and risk of spontaneous abortion. JAMA 2002;288:1867-73.
29. Grant BF, Stinson FS, Dawson DA, Chou SP, Dufour MC, Compton W, et al. Prevalence and co-occurrence of substance use disorders and independent mood and anxiety disorders: results from the National Epidemiologic Survey on Alcohol and Related Conditions. Arch Gen Psychiatry 2004;61:807-16.
30. De Jong van den Berg LT, Feenstra N, Sorensen HT, Cornel MC. Improvement of drug exposure data in a registration of congenital anomalies. Pilot-study: pharmacist and mother as sources for drug exposure data during pregnancy. EuroMAP Group. Europen Medicine and Pregnancy Group. Teratology 1999;60:33-6.
31. Olesen C, Søndergaard C, Thrane N, Nielsen GL, de Jong-van den Berg L, Olsen J. Do pregnant women report use of dispensed medications? Epidemiology 2001;12:497-501.
32. Buss L, Tolstrup J, Munk C, Bergholt T, Ottesen B, Grønbaek M, et al. Spontaneous abortion: a prospective cohort study of younger women from the general population in Denmark. Validation, occurrence and risk determinants. Acta Obstet Gynecol Scand 2006;85:467-75.